1.Investigation on the hydroxylation metabolism of imrecoxib in vitro by using recombinant human CYPs.
Qiang LI ; Hai-Hua HUANG ; Yu DONG ; Da-Fang ZHONG
Acta Pharmaceutica Sinica 2005;40(10):912-915
<p>AIMTo identify the drug-metabolizing enzymes involved in the hydroxylation of the new anti-inflammatory and anodyne imrecoxib.p><p>METHODSImrecoxib was incubated with heterologous expression human cytochrome P450 (rCYPs) in vitro, and metabolites and remained parent drug were detected with liquid chromatography-multistage mass spectrometry. The contribution of 4 CYPs in the hydroxylation metabolism of imrecoxib was evaluated by total normalized rate (TNR) method.p><p>RESULTSImrecoxib is metabolized by CYP2C9, CYP2D6 and CYP3A4, with the rate of 62.5%, 21.1% and 16.4%, respectively.p><p>CONCLUSIONCYP2C9 is the major enzyme involved in imrecoxib hydroxylation metabolism.p>
Aryl Hydrocarbon Hydroxylases
;
metabolism
;
Cyclooxygenase 2 Inhibitors
;
metabolism
;
Cytochrome P-450 CYP2C9
;
Cytochrome P-450 CYP2D6
;
metabolism
;
Cytochrome P-450 CYP3A
;
Cytochrome P-450 Enzyme System
;
metabolism
;
Hydroxylation
;
Pyrroles
;
metabolism
;
Spectrometry, Mass, Electrospray Ionization
;
Sulfides
;
metabolism
2.Metabolism of osthol in isolated hepatocytes of rat.
Li-Fang ZHANG ; Xiao HU ; Ping WANG ; Lei ZHANG
Acta Pharmaceutica Sinica 2009;44(10):1131-1135
The paper is aimed to study the metabolic characteristics of osthol (Ost) in isolated hepatocytes of rat to identify which isoforms of CYP450 were responsible for Ost metabolism in vitro. The concentration of Ost in isolated hepatocytes incubation system was determined by HPLC-UV. The effects of incubation time, substrate concentration and hepatocytes amount on the metabolic characteristics of Ost were investigated. CYP2C8 inhibitor quercetin (Que), CYP2C9 inhibitor sulfaphenazole (Sul), CYP2D6 inhibitor yohimbine (Yoh), CYP3A4 inhibitor troleandomycin (Tro) and CYP450 inducer rifampicin (Rif) were used to investigate their effects on the metabolism of Ost. The metabolism of Ost in isolated rat hepatocytes showed an enzymatic kinetic characteristics. Rif induced Ost elimination in rat hepatocytes; Yoh, Sul, Que did not have effects on Ost metabolism in vitro. Between 0-200 micromol x L(-1), Tro inhibited Ost metabolism in a concentration-dependent manner. CYP3A4 is the enzyme metabolizing Ost in vitro; CYP2C8, CYP2C9 and CYP2D6 did not involve in Ost metabolism in rat hepatocytes.
Animals
;
Cells, Cultured
;
Cnidium
;
chemistry
;
Coumarins
;
isolation & purification
;
metabolism
;
Cytochrome P-450 CYP2D6 Inhibitors
;
Cytochrome P-450 CYP3A
;
Cytochrome P-450 Enzyme Inhibitors
;
Cytochrome P-450 Enzyme System
;
Hepatocytes
;
metabolism
;
Male
;
Plants, Medicinal
;
chemistry
;
Quercetin
;
pharmacology
;
Rats
;
Rats, Sprague-Dawley
;
Rifampin
;
pharmacology
;
Sulfaphenazole
;
pharmacology
;
Troleandomycin
;
administration & dosage
;
pharmacology
;
Yohimbine
;
pharmacology
3.Identification of metabolites of epiberberine in rat liver microsomes and its inhibiting effects on CYP2D6.
Xiao-Yan YANG ; Jing YE ; Gui-Xia SUN ; Bao-Juan XUE ; Yuan-Yuan ZHAO ; Pei-Pei MIAO ; Jin SU ; Yu-Jie ZHANG
China Journal of Chinese Materia Medica 2014;39(19):3855-3859
Epiberberine, one of the most important isoquinoline alkaloid in Coptidis Rhizoma, possesses extensive pharmacological activities. In this paper, the liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used to study phase I and phase II metabolites. A Thermo HPLC system (including Surveyor AS, Surveyor LC Pump, Surveyor PDA. USA) was used. The cocktail probe drugs method was imposed to determine the content change of metoprolol, dapsone, phenacetin, chlorzoxazone and tolbutamide simultaneously for evaluating the activity of CYP2D6, CYP3A4, CYP1A2, CYP2E1 and CYP2C9 under different concentrations of epiberberine in rat liver microsomes. The result showed that epiberberine may have phase I and phase II metabolism in the rat liver and two metabolites in phase I and three metabolites in phase II are identified in the temperature incubation system of in vitro liver microsomes. Epiberberine showed significant inhibition on CYP2D6 with IC50 value of 35.22 μmol L(-1), but had no obvious inhibiting effect on the activities of CYP3A4, CYP1A2, CYP2E1 and CYP2C9. The results indicated that epiberberine may be caused drug interactions based on CYP2D6 enzyme. This study aims to provide a reliable experimental basis for its further research and development of epiberberine.
Animals
;
Berberine
;
analogs & derivatives
;
chemistry
;
metabolism
;
Chromatography, High Pressure Liquid
;
Cytochrome P-450 CYP2D6
;
metabolism
;
Cytochrome P-450 CYP2D6 Inhibitors
;
chemistry
;
metabolism
;
Drugs, Chinese Herbal
;
chemistry
;
metabolism
;
Male
;
Microsomes, Liver
;
drug effects
;
enzymology
;
metabolism
;
Molecular Structure
;
Rats
;
Rats, Sprague-Dawley
;
Tandem Mass Spectrometry
4.Drug Interactions between Cardiovascular Agents and Psychotropic Drugs.
Korean Journal of Psychosomatic Medicine 2011;19(2):57-65
There are numerous drug interactions related to many psychotropic and cardiovascular medications. Firstly, the principles in predicting drug interactions are discussed. Cytochrome P (CYP) 450 plays a significant role in the metabolism of these drugs that are substrates, inhibitors, or inducers of CYP450 enzymes. The two most significant enzymes are CYP2D6 and CYP3A4. The ability of psychotropic drugs to act as inhibitors for the enzymes may lead to altered efficacy or toxicity of co-administered cardiovascular agents as a substrate for the enzymes. The following is also a review of the known interactions between many commonly prescribed cardiovascular agents and psychotropic drugs. Most beta blockers are metabolized by CYP2D6, which may lead to drug toxicity when they use in combination with potent CYP2D6 inhibitors including bupropion, chlorpromazine, haloperidol, selective serotonin reuptake inhibitors, and quinidine. Concomitant administration of lithium with angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and diuretics may increase serum lithium concentrations and toxicity. Calcium channel blockers and cholesterol lowering agents are subject to interactions with potent inhibitors of CYP3A4, such as amiodarone, diltiazem, fluvoxamine, nefazodone, and verapamil. Prescribing antiarrhythmic drugs in conjunction with medications are known to prolong QT interval and/or inhibitors on a relevant CYP450 enzyme is generally not recommended, or needs watchful monitoring. Digoxin and warfarin also have warrant careful monitoring if co-administered with psychotropic drugs.
Amiodarone
;
Angiotensin Receptor Antagonists
;
Angiotensin-Converting Enzyme Inhibitors
;
Anti-Arrhythmia Agents
;
Bupropion
;
Calcium Channel Blockers
;
Cardiovascular Agents
;
Chlorpromazine
;
Cholesterol
;
Cytochrome P-450 CYP2D6
;
Cytochrome P-450 Enzyme System
;
Cytochromes
;
Digoxin
;
Diltiazem
;
Diuretics
;
Drug Interactions
;
Drug Toxicity
;
Fluvoxamine
;
Haloperidol
;
Lithium
;
Psychotropic Drugs
;
Quinidine
;
Serotonin Uptake Inhibitors
;
Triazoles
;
Verapamil
;
Warfarin
5.Adjuvant Hormonal Therapy: Current Standard and Practical Issues.
Byeong Woo PARK ; Hyung Seok PARK
Journal of Breast Cancer 2010;13(3):242-249
Adjuvant hormonal therapy is used as the first target-specific approach in curing breast cancers due to its high efficacy and mild side effects. Five years of tamoxifen therapy has been the gold standard for women with estrogen receptor-positive breast cancer irrespective of age or menopausal and nodal status. After the emergence of 3rd generation aromatase inhibitors (AI), the use of either tamoxifen or tamoxifen plus ovarian function suppression for 5 years has been proposed as an acceptable standard for premenopausal women while AI should form part of standard endocrine therapy for the postmenopausal women as established at the St. Gallen Concensus Conference. The addition of luteinizing-hormone-releasing hormone (LHRH) analogs might be beneficial for the younger patients who remain premenopausal after chemotherapy, however controversies over the addition of LHRH analogs remains. Further, it has been suggested that CYP2D6 polymorphisms and concomitant use of CYP2D6 inhibitors which reduce CYP2D6 activity may influence the clinical outcomes of adjuvant tamoxifen therapy. The androgen receptor has been evaluated as a prognostic or predictive marker for endocrine responsiveness in a few studies; however, there are many issues to be answered and ongoing clinical trials will provide the answers. Until then, it would be important for clinicians to carefully evaluate the risk factors of patients, monitor the compliance of those patients who are under endocrine therapy, and take care in selecting antidepressants when coprescription with tamoxifen is necessary. In the future, tailored therapy will be designed based on the target molecular profiling of the tumors, pharmacogenomics, and improved understanding of receptor signaling biology. More attention should be given to explore molecular markers that could differentiate the subsets for tailoring.
Antidepressive Agents
;
Antineoplastic Agents, Hormonal
;
Aromatase Inhibitors
;
Biology
;
Breast
;
Breast Neoplasms
;
Compliance
;
Cytochrome P-450 CYP2D6
;
Estrogens
;
Female
;
Gonadotropin-Releasing Hormone
;
Humans
;
Organothiophosphorus Compounds
;
Pharmacogenetics
;
Receptors, Androgen
;
Risk Factors
;
Tamoxifen
6.A precision medication study of atomoxetine in children with attention deficit hyperactivity disorder: CYP2D6 genetic testing and therapeutic drug monitoring.
Di FU ; Hong-Li GUO ; Ya-Hui HU ; Feng CHEN
Chinese Journal of Contemporary Pediatrics 2023;25(1):98-103
Atomoxetine is the first non-stimulant drug for the treatment of children and adults with attention deficit hyperactivity disorder (ADHD), and its safety and efficacy show significant differences in the pediatric population. This article reviews the genetic factors influencing the pharmacokinetic differences of atomoxetine from the aspect of the gene polymorphisms of the major metabolizing enzyme CYP2D6 of atomoxetine, and then from the perspective of therapeutic drug monitoring, this article summarizes the reference ranges of the effective concentration of atomoxetine in children with ADHD proposed by several studies. In general, there is an association between the peak plasma concentration of atomoxetine and clinical efficacy, but with a lack of data from the Chinese pediatric population. Therefore, it is necessary to establish related clinical indicators for atomoxetine exposure, define the therapeutic exposure range of children with ADHD in China, and combine CYP2D6 genotyping to provide support for the precision medication of atomoxetine.
Adult
;
Child
;
Humans
;
Adrenergic Uptake Inhibitors/therapeutic use*
;
Atomoxetine Hydrochloride/therapeutic use*
;
Attention Deficit Disorder with Hyperactivity/genetics*
;
Cytochrome P-450 CYP2D6/therapeutic use*
;
Drug Monitoring
;
Genetic Testing
;
Propylamines/therapeutic use*
;
Treatment Outcome
7.Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines.
Sollip KIM ; Yeo Min YUN ; Hyo Jin CHAE ; Hyun Jung CHO ; Misuk JI ; In Suk KIM ; Kyung A WEE ; Woochang LEE ; Sang Hoon SONG ; Hye In WOO ; Soo Youn LEE ; Sail CHUN
Annals of Laboratory Medicine 2017;37(2):180-193
Pharmacogenetic testing for clinical applications is steadily increasing. Correct and adequate use of pharmacogenetic tests is important to reduce unnecessary medical costs and adverse patient outcomes. This document contains recommended pharmacogenetic testing guidelines for clinical application, interpretation, and result reporting through a literature review and evidence-based expert opinions for the clinical pharmacogenetic testing covered by public medical insurance in Korea. This document aims to improve the utility of pharmacogenetic testing in routine clinical settings.
Anticoagulants/therapeutic use
;
Antidepressive Agents/therapeutic use
;
Antimetabolites, Antineoplastic/therapeutic use
;
Antitubercular Agents/therapeutic use
;
Arylamine N-Acetyltransferase/genetics
;
Coronary Artery Disease/drug therapy/genetics
;
Cytochrome P-450 CYP2C19/genetics
;
Cytochrome P-450 CYP2C9/genetics
;
Cytochrome P-450 CYP2D6/genetics
;
Depressive Disorder/drug therapy/genetics
;
Genotype
;
Isoniazid/therapeutic use
;
Laboratories, Hospital/standards
;
Methyltransferases/genetics
;
Pharmacogenomic Testing/*methods/standards
;
Platelet Aggregation Inhibitors/therapeutic use
;
Pulmonary Embolism/drug therapy/genetics
;
Ticlopidine/analogs & derivatives/therapeutic use
;
Tuberculosis/drug therapy/genetics
;
Vitamin K Epoxide Reductases/genetics
;
Warfarin/therapeutic use
8.Nonresponders to Daily Paroxetine and Another SSRI in Men With Lifelong Premature Ejaculation: A Pharmacokinetic Dose-Escalation Study for a Rare Phenomenon.
Paddy K C JANSSEN ; Daan TOUW ; Dave H SCHWEITZER ; Marcel D WALDINGER
Korean Journal of Urology 2014;55(9):599-607
PURPOSE: Nonresponse to any selective serotonin reuptake inhibitor (SSRI) treatment is rare. In this study, we aimed to investigate ejaculation delay nonresponse to paroxetine treatment in men with lifelong premature ejaculation (PE) who were also known to be nonresponders to other SSRIs. MATERIALS AND METHODS: Five males with lifelong PE who were known nonresponders to paroxetine and other serotonergic antidepressants and eight males with lifelong PE who were specifically recruited were included. Blood sampling occurred 1 month and 1 day before the start of treatment and at the end of three consecutive series of 4 weeks of daily treatment with 10-, 20-, and 30-mg paroxetine, respectively. Blood samples for measurement of leptin and paroxetine were taken at 8:30 AM, 9:30 AM, 10:30 AM, and 11:30 AM, respectively. At 9:00 AM, one tablet of 10-, 20-, or 30-mg paroxetine was taken during the first, second, and third month, respectively. Intravaginal ejaculatory latency time (IELT) was measured with a stopwatch. The main outcome measures were the fold increase in the geometric mean IELT, serum leptin and paroxetine concentrations, body mass index (BMI), 5-HT1A receptor C-1019G polymorphism, and CYP2D6 mutations. RESULTS: Between the 7 paroxetine responders and 6 nonresponders, the fold increase in the geometric mean IELT was significantly different after daily 10-mg (p=0.003), 20-mg (p=0.002), and 30-mg paroxetine (p=0.026) and ranged from 2.0 to 8.8 and from 1.1 to 1.7, respectively. BMI at baseline and at the end of the study was not significantly different between responders and nonresponders. Serum leptin levels at baseline were similar in responders and nonresponders and did not change during treatment. The serum paroxetine concentration increased with increasing dosage and was not significantly different between responders and nonresponders. There was no association between the fold increase in the geometric mean IELT and serum paroxetine levels during the three treatment periods nor between leptin levels during the treatment periods and serum paroxetine levels. For the 5-HT1A receptor C-1019G variation, all responders had the CC genotype and all nonresponders had the GC genotype, respectively. CONCLUSIONS: Complete absence of paroxetine-induced ejaculation delay is presumably related to pharmacodynamic factors and perhaps to 5-HT1A receptor gene polymorphism.
Adolescent
;
Adult
;
Aged
;
Body Mass Index
;
Cytochrome P-450 CYP2D6/genetics
;
Humans
;
Leptin/blood
;
Male
;
Middle Aged
;
Mutation
;
Paroxetine/*administration & dosage/blood
;
Polymorphism, Genetic
;
Premature Ejaculation/*drug therapy/genetics
;
Receptor, Serotonin, 5-HT1A/genetics
;
Risk Factors
;
Serotonin Uptake Inhibitors/*administration & dosage
;
Time Factors
;
Treatment Outcome
;
Young Adult
9.Nonresponders to Daily Paroxetine and Another SSRI in Men With Lifelong Premature Ejaculation: A Pharmacokinetic Dose-Escalation Study for a Rare Phenomenon.
Paddy K C JANSSEN ; Daan TOUW ; Dave H SCHWEITZER ; Marcel D WALDINGER
Korean Journal of Urology 2014;55(9):599-607
PURPOSE: Nonresponse to any selective serotonin reuptake inhibitor (SSRI) treatment is rare. In this study, we aimed to investigate ejaculation delay nonresponse to paroxetine treatment in men with lifelong premature ejaculation (PE) who were also known to be nonresponders to other SSRIs. MATERIALS AND METHODS: Five males with lifelong PE who were known nonresponders to paroxetine and other serotonergic antidepressants and eight males with lifelong PE who were specifically recruited were included. Blood sampling occurred 1 month and 1 day before the start of treatment and at the end of three consecutive series of 4 weeks of daily treatment with 10-, 20-, and 30-mg paroxetine, respectively. Blood samples for measurement of leptin and paroxetine were taken at 8:30 AM, 9:30 AM, 10:30 AM, and 11:30 AM, respectively. At 9:00 AM, one tablet of 10-, 20-, or 30-mg paroxetine was taken during the first, second, and third month, respectively. Intravaginal ejaculatory latency time (IELT) was measured with a stopwatch. The main outcome measures were the fold increase in the geometric mean IELT, serum leptin and paroxetine concentrations, body mass index (BMI), 5-HT1A receptor C-1019G polymorphism, and CYP2D6 mutations. RESULTS: Between the 7 paroxetine responders and 6 nonresponders, the fold increase in the geometric mean IELT was significantly different after daily 10-mg (p=0.003), 20-mg (p=0.002), and 30-mg paroxetine (p=0.026) and ranged from 2.0 to 8.8 and from 1.1 to 1.7, respectively. BMI at baseline and at the end of the study was not significantly different between responders and nonresponders. Serum leptin levels at baseline were similar in responders and nonresponders and did not change during treatment. The serum paroxetine concentration increased with increasing dosage and was not significantly different between responders and nonresponders. There was no association between the fold increase in the geometric mean IELT and serum paroxetine levels during the three treatment periods nor between leptin levels during the treatment periods and serum paroxetine levels. For the 5-HT1A receptor C-1019G variation, all responders had the CC genotype and all nonresponders had the GC genotype, respectively. CONCLUSIONS: Complete absence of paroxetine-induced ejaculation delay is presumably related to pharmacodynamic factors and perhaps to 5-HT1A receptor gene polymorphism.
Adolescent
;
Adult
;
Aged
;
Body Mass Index
;
Cytochrome P-450 CYP2D6/genetics
;
Humans
;
Leptin/blood
;
Male
;
Middle Aged
;
Mutation
;
Paroxetine/*administration & dosage/blood
;
Polymorphism, Genetic
;
Premature Ejaculation/*drug therapy/genetics
;
Receptor, Serotonin, 5-HT1A/genetics
;
Risk Factors
;
Serotonin Uptake Inhibitors/*administration & dosage
;
Time Factors
;
Treatment Outcome
;
Young Adult